secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001837607-25-000084
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma reports positive ABP-450 biosimilarity data, secures $6M PIPE and debt reduction
--------------------------------------------------------------------------------

- ABP-450 shows 100% amino-acid sequence identity to BOTOX (93-99% coverage across five proteins) and highly similar functional characteristics.
- FDA Type 2a meeting scheduled for November 19, 2025 to review analytical package ahead of biosimilar pathway.
- $6M PIPE and Daewoong note exchange expected to reduce outstanding debt by over 90% and extend cash runway into Q2 2026.
- Cash and equivalents $5.9M as of Sep 30, 2025; combined financing expected to fund operations through Q2 2026.
- ABP-450 has global approval in 69 countries, supporting fully scaled manufacturing platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/0001837607-25-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer